Family history of inflammatory bowel disease among patients with ulcerative colitis: A systematic review and meta-analysis

Clinical presentations 310Investigation 311Clinical course 311Management 31225% of inflammatory bowel disease presents in childhood, 1/3 as ulcerative colitis. Presentation can occur at any age and ulcerative colitis is the commonest cause of inflammatory bowel disease in the younger child. Family history of Crohn's disease or ulcerative colitis is common in index cases....

Download Full-text

Inflammatory bowel disease: introduction

10.1093/med/9780198569862.003.0041 ◽

2011 ◽

Cited By ~ 1

Author(s):

R. Mark Beattie ◽

Anil Dhawan ◽

John W.L. Puntis

Keyword(s):

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Crohn’S Disease ◽

Family History ◽

Crohn's Disease ◽

Bowel Disease ◽

History Of ◽

Inflammatory Bowel ◽

The Uk

Inflammatory bowel disease 288• 25 % of inflammatory bowel disease (IBD) presents in childhood, usually as Crohn's disease or ulcerative colitis. The UK incidence is 5.2/100 000 children <16 years of age. Crohn's disease is the more common. Family history of Crohn's disease or ulcerative colitis is common. Both diseases can occur in the same family....

Download Full-text

The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis

Journal of Patient-Centered Research and Reviews ◽

10.17294/2330-0698.1722 ◽

2020 ◽

Vol 7 (2) ◽

pp. 189-205

Author(s):

Aaron Yarlas ◽

Stephen Maher ◽

Martha Bayliss ◽

Andrew Lovley ◽

Joseph C Cappelleri ◽

...

Keyword(s):

Systematic Review ◽

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Meta Analysis ◽

Controlled Trials ◽

Inflammatory Bowel Disease Questionnaire ◽

Randomized Controlled ◽

Inflammatory Bowel ◽

Disease Questionnaire

Download Full-text

P344 Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.468 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S367-S368

Author(s):

J Hanzel ◽

A Strik ◽

K Gecse ◽

G D’Haens ◽

E Dreesen

Keyword(s):

Systematic Review ◽

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Adverse Events ◽

Random Effects ◽

Bowel Disease ◽

Clinical Remission ◽

De Novo ◽

Meta Analysis ◽

Inflammatory Bowel

Abstract Background Switching from originator infliximab (IFX) to the CT-P13 biosimilar is a widespread practice, although some concerns persist, particularly about long-term outcomes. We performed a systematic review and meta-analysis to assess the effectiveness and safety of switching from originator IFX to CT-P13 in patients with inflammatory bowel disease (IBD). Methods We systematically searched electronic databases for randomised controlled trials and prospective observational studies of adult patients with IBD who had switched from originator IFX to CT-P13 and were followed up for at least 12 months. The main outcomes were the pooled rate of clinical remission (as defined by the included studies) and adverse events at 12 months. Secondary outcomes included the rate of treatment discontinuation and de novo immunogenicity. A DerSimonian-Laird random-effects meta-analysis of proportions with double arcsine transformation was performed. Variables judged to be clinically important were studied in an exploratory random-effects meta-regression analysis. Results Eleven studies with 1204 patients (71% with Crohn’s disease [CD]) switching from originator IFX to CT-P13 were identified. Pooled rates of clinical remission at 12 months were 83.6% in ulcerative colitis (UC), 75.9% in CD, and 79.6% in mixed cohorts (Figure 1). Clinical remission at 12 months was negatively associated with combined immunosuppression at switch (7% decrease in remission at 12 months per 10% increase in patients receiving combination therapy) and positively associated with remission at switch (6% increase in remission at 12 months per 10% increase in remission at switch). The pooled rate of adverse events at 12 months was 21.0% (95% confidence interval [CI] 10.4–34.1%). Pooled rates of treatment discontinuation at 12 months were 24.4% (95% CI 12.0–39.4%) in UC, 18.6% (95% CI 8.8–30.9%) in CD, and 13.1% (95% CI 0.7–35.6%) in mixed cohorts. De novo immunogenicity was rare (3.3%, 95% CI 1.5–5.6%). All estimates had at least moderate heterogeneity. Figure 1: Meta-analysis of clinical remission rates at 12 months after switching from originator infliximab to CT-P13 in ulcerative colitis and Crohn’s disease. Conclusion Switching from originator IFX to CT-P13 appears to be effective and safe, although these findings should be interpreted in the context of the limitations of the primary publications which lacked control arms. Combined immunosuppression at switch, potentially as a marker of disease severity, was negatively associated with clinical remission at 12 months after the switch.

Download Full-text

Liver Transplantation, IBD Clinical Course, Is There a Link? A Systematic Review and Meta-Analysis Protocol

10.21203/rs.3.rs-93114/v1 ◽

2020 ◽

Author(s):

GholamReza Sivandzadeh ◽

Manoosh Mehrabi ◽

Ali Reza Safarpour ◽

Hadis Ashrafizadeh ◽

Abbas Ali Keshtkar

Keyword(s):

Systematic Review ◽

Ulcerative Colitis ◽

Inflammatory Bowel Disease ◽

Liver Transplantation ◽

Publication Bias ◽

Bowel Disease ◽

Clinical Course ◽

Meta Analysis ◽

Effect Model ◽

Inflammatory Bowel

Abstract BackgroundPrimary sclerosing cholangitis (PSC) is an uncommon chronic and progressive cholestatic liver disease. There is a robust association between PSC and Inflammatory Bowel Disease (IBD), usually Ulcerative Colitis (UC). According to the review of literature, the incidence of de novo IBD after solid organ transplantation (SOT) is found to be higher than general population. Considering lacking of any systematic review and pursuing debate on the clinical course and risk factors of IBD activity after Liver Transplantation (LT), the present study will be performed with a focus investigation on the correlation of IBD clinical course with liver transplantation. MethodsIn this systematic review, the electronic databases including PubMed/MEDLINE, Scopus, WoS (Clarivate Analytics), Embase (Embase.com), and ProQuest will be searched. Our search strategy (i.e. The eligibility criteria) covers prospective and retrospective observational studies that evaluated the clinical course of ulcerative colitis or/and Crohn’s disease after liver transplantation with no language limitation published between 1970.01.01 and 2020.03.30. The selection phase, data extraction and quality assessment will be independently implemented by two authors. In case of any disagreement between the authors, the issue will be resolved by consensus; if not resolved, the opinion of a third expert will be asked. We will use one of the following two models: Random Effect Model or Fixed Effect Model according to the severity of methodological heterogeneity and forest plot will present the combination of data obtained from all finally included studies, to show the separated and combined frequency and their corresponding 95% CIs. Statistical heterogeneity will be evaluated by the Q-statistic test and I2 statistics. Funnel plot for assessing the potential reporting bias, Begg's and Egger's tests for meaningful results of the publication bias, and the Fill & Trim method for corrected publication bias will be used. DiscussionThis systematic review and meta-analysis study will clarify the correlation of IBD clinical course with liver transplantation. Because of the importance of inflammatory bowel disease, if the future study reveals consistent results, it will be clinically beneficial for physicians and other health care professionals to better manage inflammatory bowel disease after liver transplantation.Systematic review registrationPROSPERO, CRD42020179412.

Download Full-text